Adolph V, Heaton J, Steiner R, Bonis S, Falterman K, Arensman R
Section of Pediatric Surgery, Ochner Clinic, New Orleans, LA.
J Pediatr Surg. 1991 Mar;26(3):326-30; discussion 330-2. doi: 10.1016/0022-3468(91)90511-q.
Extracorporeal membrane oxygenation (ECMO) has been used for 20 years in neonates and children with cardiac and respiratory failure. The number of neonates treated with ECMO has increased exponentially, but the number of older children treated is small. The selection and exclusion criteria for pediatric ECMO are poorly defined, and the results vary because of variable selection criteria and institutional experience with the technique. In order to help define the role of pediatric ECMO, we reviewed our experience in noneonatal pediatric respiratory failure. We have treated 22 patients ranging in age from 1 to 105 months and ranging in weight from 3 to 35 kg. Eighteen patients met the criteria for adult respiratory distress syndrome, two had respiratory syncytial virus pneumonia, and one had severe barotrauma complicating the management of reactive airway disease. All patients were considered by the referring institutions and by us to be failing conventional management as evidenced by hypoxia, hypercarbia, excessive ventilatory pressures, or progressive barotrauma. All were considered likely to die with continued conventional management. Sixteen of the 22 patients had complications (73%), but half of the last 10 patients had no complications. Hemorrhagic complications occurred in 12 patients. Mechanical complications included membrane failure, raceway rupture, pump malfunction, and improper cannula positioning. Other complications included culture-proven infection and renal failure. Eleven of the 22 patients survived (50%); nine of the last 12 survived (75%). These results suggest that ECMO may be a useful technique in selected pediatric patients with respiratory failure. Survival and complication rates improve as experience with the technique increases.
体外膜肺氧合(ECMO)已在患有心脏和呼吸衰竭的新生儿及儿童中应用了20年。接受ECMO治疗的新生儿数量呈指数增长,但接受治疗的大龄儿童数量较少。儿科ECMO的选择和排除标准定义不明确,由于选择标准的差异和各机构对该技术的经验不同,结果也有所不同。为了帮助明确儿科ECMO的作用,我们回顾了我们在非新生儿儿科呼吸衰竭方面的经验。我们共治疗了22例患者,年龄从1个月至105个月不等,体重从3千克至35千克不等。18例患者符合成人呼吸窘迫综合征的标准,2例患有呼吸道合胞病毒肺炎,1例患有严重气压伤并使反应性气道疾病的治疗复杂化。所有患者均被转诊机构和我们认为常规治疗失败,表现为低氧血症、高碳酸血症、过高的通气压力或进行性气压伤。所有患者如继续接受常规治疗均可能死亡。22例患者中有16例出现并发症(73%),但最后10例患者中有一半没有并发症。出血性并发症发生在12例患者中。机械并发症包括膜肺故障、管道破裂、泵故障和插管位置不当。其他并发症包括经培养证实的感染和肾衰竭。22例患者中有11例存活(50%);最后12例中有9例存活(75%)。这些结果表明,ECMO对于某些患有呼吸衰竭的儿科患者可能是一种有用的技术。随着对该技术经验的增加,存活率和并发症发生率会有所改善。